Panandiker Kaya Kamlesh Pai
CIK: 0002095250
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
LBRX
LB PHARMACEUTICALS INC
Officer
Discretionary Trading P&L
Holdings
About Pai Panandiker Kaya Kamlesh
Pai Panandiker Kaya Kamlesh (SEC CIK 0002095250) files insider reports with the SEC as Chief Commercial Officer of LB PHARMACEUTICALS INC (LBRX).
Signal8 holds 2 ownership filings by Pai Panandiker Kaya Kamlesh (1 Form 3, 1 Form 4), filed between Nov 18, 2025 and Dec 11, 2025. Those filings report 1 transaction, the latest on Dec 10, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Pai Panandiker Kaya Kamlesh's filings is in NEW YORK, NY.
Recent filings by Pai Panandiker Kaya Kamlesh
- Dec 10, 2025: Grant or award of LBRX derivative securities (Form 4, code A).
Other insiders filing for LB PHARMACEUTICALS INC (LBRX)
- Miller Joseph M, Chief Financial Officer
- Kozauer Susan Gani, Chief Medical Officer
- Deep Track Biotechnology Master Fund, Ltd., 10% Owner
- RUFFOLO ROBERT R, Director
- Nussbaum Ran, Director
- Luse Rebecca, Director